Activity of epidermal growth factor tyrosine kinase inhibitors in non-small cell lung carcinoma with refractory leptomeningeal metastases.
Fiche publication
Date publication
mai 2019
Journal
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BEAU-FALLER Michèle
Tous les auteurs :
Flippot R, Biondani P, Auclin E, Xiao D, Hendriks L, Le Rhun E, Leduc C, Beau-Faller M, Gervais R, Remon J, Adam J, Planchard D, Lavaud P, Naltet C, Caramella C, Le Pechoux C, Lacroix L, Gazzah A, Mezquita L, Besse B
Lien Pubmed
Résumé
Leptomeningeal metastases (LM) are associated with dismal prognosis in non-small cell lung cancer (NSCLC). Optimal management remains unknown in EGFR-mutated NSCLC patients after initial tyrosine kinase inhibitor (TKI) failure.
Mots clés
Non-small cell lung carcinoma, epidermal growth factor receptor, leptomeningeal metastases, tyrosine kinase inhibitor
Référence
J Thorac Oncol. 2019 May 17;: